Quick Answer
Can-Fite BioPharma Ltd. reported Stockholders Equity of $5.59 million for fiscal year 2025.
Can-Fite BioPharma Ltd. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $5.59M | +2.9% |
| 2024 | $5.44M | -12.9% |
| 2023 | $6.24M | +39.6% |
| 2022 | $4.47M | -68.9% |
| 2021 | $14.38M | +136.8% |
| 2020 | $6.07M | +148.7% |
| 2019 | $2.44M | -19.0% |
| 2018 | $3.02M | +1.0% |
| 2017 | $2.98M | — |
- Can-Fite BioPharma Ltd. showed an increase of +2.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, Can-Fite BioPharma Ltd.’s stockholders equity has grown by 87.4% (from $2.98 million to $5.59 million).
- The most recent figure is from Can-Fite BioPharma Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: